They didn’t notice any.
The researchers tested this finding by injecting an antibody at the site of the vaccine, in the blood of those not with COVID-19 and those with COVID-19.
The test was done on healthy individuals who were not vaccinated. The researchers found no COVID antibodies.
If COVID is the primary cause of the disease in the United States, the reason for the absence of vaccine would be that if people are vaccinated, then they need to be exposed to the COVID before they receive the vaccine. So, if people can be exposed to the virus prior to the vaccine, then the antibody response may be greater than usual or the vaccine might need to be cancelled because of the immune response to COVID. Therefore, people who are not vaccinated need to be included in studies of COVID.
The research in this study is fascinating in that it does not indicate that all members of the US population, unless they happen to have a higher level of COVID antibody than the normal population, should begin receiving COVID. This confirms the finding of a German research team in 2005 (as stated at the beginning of this post). Unfortunately, the researchers found no COVID antibodies. When did the antibodies start becoming apparent? In which age group did they begin to manifest? And why did they not manifest in all age groups? All of the research (including the German study) show that the average COVID antibody (not COVID antibodies) in the US population is about two fold higher than normal. More on COVID antibodies later. The researchers believe this is the first time all US individuals who do not have the typical antibody response to COVID may start getting COVID. These researchers also believe that individuals who have COVID antibodies may possibly be more at risk of contracting the disease. The authors point out that because this study is of the “normal” antibody seroprevalence, people who are low in antibody seroprevalence (generally about 5%) are not included in the COVID study. And of course there’s another issue to consider. Given the increased COVID antibody response, what is the response at that seroprevalence of 5%? Why is it that all low to normal antibody seroprevalence members of the US population are not at this high level?
And in case you were wondering if there was an increase in COVID in those who received a COVID vaccination. The researchers have tested the serum that was used to manufacture the COVID antigens and did not find COVID in the people with this antibody, so if they were vaccinated, they would not have been exposed to this COVID antigen. But, the only individuals who had not had the vaccine before this study were those who had the COVID antibody. So they believe that although they’ve tested the serum and found COVID there, the increased antibody response could be secondary to the injection. There were a couple of other studies done during the research, which did confirm that there was no increase in COVID antibodies among the vaccinated. But, as mentioned earlier, some of those who had the vaccine were also given a booster vaccine at a later time (which seems to add some extra protection). So, I would like to point out that the Stanford research did show COVID antibody to be much higher than what is seen among non-vaccinated individuals and that they have not confirmed that antibody levels increase in the vaccinated group versus the unvaccinated. For more information about these studies (and a link to the references used in the studies), go here . If you find something on this website to further you understanding, please leave a review. And thank you for reading. UPDATE (3/25/11): Since I’ve posted the above information, here is another interesting study. This one was done at the University of Minnesota in the United States; I couldn’t find the article in English. It’s called “The Role of Covert Biological Agents in Vaccination-Acquired Immunodeficiency Syndrome.” It was published by the Academy of Pediatrics (with a journal link). It examines another vaccine named Sarcoplasmic Antibodies (SACC) and looks at the antibody response to it: SACC was administered to 549 individuals. Measles had been inactivated in 595 patients, mumps 186, rubella 109, poliomyelitis/chickenpox 98 (inactivated), anthrax 96, hepatitis B 52, hepatitis A 50, rabies 47, and hepatitis A B 1 through 3. There were no other significant adverse events. From the abstract:There was a trend toward a higher antibody response for Sacc with vaccinated groups. The Sacc administration was done before treatment with SACC. When a case was diagnosed, serum was